The Bio Protocol DeSci leader has launched V1 on both Base and Solana to let decentralized science research funding use AI and blockchain efficiency. Bio Protocol’s V1 expansion turns the platform into an entirely new financial system that allows anyone access to the science funding market. The V1 update enables BIO token utility enhancements and creates fresh income opportunities as it transforms how DeSci operates.
From Gatekeeper to Open Door: The BioDAO Launchpad
The old process of manually selecting programs no longer exists. Through its BioDAO Launchpad, Bio V1 gives total access to biotech projects that want to be on the network. It’s a three-step dance:
- People holding BIO tokens can lock in their tokens as part of voting procedures, giving them an equal say despite any business elites governing the rules.
- Grant recipients access capital by running online auctions and investment odds-and-sods that resemble crypto crowdfunding.
When a project raises enough money, the platform automatically creates tokens for exchange platforms while keeping the funds generated locked.
If a project succeeds in gaining backing, the project team receives BioDAO tokens at a discount, and the supporters recover their invested funds. The co-founder, Paul Kohlhaas, explains why BioDAO goes against biotech (The Block interview). Through V1, “BioDAO hands control of its key functions to worldwide communities of researchers, patients, and crypto enthusiasts who launch new development work. The BioDAO utility program has provided $15 million to rare disease and quantum biology research since its launch last November, showing a strong ongoing ability to fund medical science.
BioAgents: AI Muscle for Science
The key feature of this upgrade is BioAgents, which powers its capabilities. Through this AI power, the system operates two separate teams:
- Core Agents: On-chain MVPs handling treasury, governance, and grunt work—think tireless digital clerks.
- BioAgent Fleet uses advanced scientific bots to decode data and develop research plans for supported BioDAO operations.
As Kohlhaas states, BIOAgents create AI automation tools with blockchain transparency features. Technology enables faster scientific advancements by using artificial intelligence to lower expenses. Early wins? The BioDAO initiative supports research through Curetopia trials and Long COVID Labs developments, while MycoDAO generates profits from pharmaceutical patents. The system generates its own motivation to drive better ideas.
The BIO Token Earns More Value by Serving Many Purposes While Collecting Money
Stop thinking of BIO tokens as voting tools since they have real value now. On V1, the BIO token serves three functions: deploying for selection services, running BioAgents, and producing new money streams.
- Asset Management: Fees from BioDAO treasuries.
- Launchpad thus allocates a specific portion of funding round proceeds.
- Liquidity Provision: Rewards for DEX pools.
- Agent Services: Payoffs from AI-driven outputs.
Biodeg released BIO onto the Ethereum network in January 2025 and created an airdrop benefit for BioDAO investors on Binance. Bio operates effectively in DeSci, with $34 million dedicated to global research through YZi Labs and $30 million supported by Bio this year.
It’s a Big Deal
The traditional science funding process takes too long because grant availability decreases while limiting development movement. Bio V1 combines Base and Solana speed with artificial intelligence to build a smarter bio technology community. Our organization takes action whenever central systems run into trouble, according to Kohlhaas. Bio V1 serves to scale up and make lifesaving medical breakthroughs available that differ from mere industry talk.
Many satisfied users logged into X to praise DeSci’s latest delivery. According to an observer, the BOARD functions like an ETH for biomedical technology. The market feels positive about Bio DAO V1, even though people view its progress differently. Through the V1 Platform, Bio Protocol seeks to lead a research and development transformation for DeSci.
Bio Protocol expects rapid growth through its association with cost-efficient Solana and Base’s connection to Ethereum platforms. Curetopia’s $1.77 million venture suggests they will establish new BioDAOs for rare diseases alongside further medical research trials and positive outcomes. The rise of V1 could create a major DeSci movement or face challenges because of its expansion goals. BIO investors and biotech companies equally observe this development in the market.
